Huntington's Disease Research Group

Research Overview




  • Huntington's Research Group Victoria
  • LaTrobe University
  • Law Faculty, The University of Melbourne
  • Legal Services Board


  • Huntington's Study Group (HSG), USA
  • University of Iowa
  • University of Rochester
  • Indiana University
  • Ulm University, Germany
  • Coriell Medical Research Institute
  • European Huntington's Disease Network


  • 2015. Enroll-HD.  Sponsor:  CHDI
  • 2014-2015. Pride-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease. Sponsor: Teva Branded Pharmaceutical Products R&D.
  • 2014 – 2015.  An Open-Label, Long Term Safety Study of SD-809 ER in Participants with Chorea Associated with Huntington Disease’ (ARC-HD). Auspex Pharmaceuticals, Inc.
  • 2012 – 2014 .  A randomized, double-blind, placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington’s disease (REACH2HD). Sponsor: Prana Biotech.
  • 2007 – 2014.  Neurobiological Predictors of Huntington’s Disease (PREDICT-HD). Sponsor: National Institutes of Health, USA; CHDI Foundation.
  • 2009 – 2011. Phase 3 Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington’s Disease (HORIZON)- Medication/ Pfizer
  • 2012. The Jack Brockhoff Foundation Medical Research Grant: Tongue pressures, speech and swallowing function in people with Huntington’s disease.
    2009 – 2012. The Functional Rating Scale Taskforce for pre-HD (FuRST-pHD). CHDI Foundation

Research Projects

Currently no project details available

Research Themes


Areas of Excellence

Neuroscience and Psychiatry

Key Contact

For further information about this research, please contact
Dr Anita Goh.

Department / Centre